Dr. Ulrich W. Mueller, 47, has been named the new Chief Operating Officer at Houston-based biotechnology company Bio-Path Holdings. Dr. Mueller, the ex-Vice President of the Fred Hutchinson Center Research Center, is now responsible for the company’s drug development, licensing, and intellectual property activities.
Bio-Path is currently developing a liposomal delivery technology for nucleic acid cancer drugs, and Dr. Mueller will be managing the Company’s clinical trials, pre-clinical, and research and development efforts.
Peter Nielsen, President and Chief Executive Officer of Bio-Path, commented that the team is very excited to have someone with Ulrich’s credentials joining Bio-Path’s management. “His extensive clinical oncology development expertise, coupled with his business development and licensing experience, will be a tremendous asset to the Company,” Nielsen said.
Dr. Mueller is the ex-Vice President of one of the leading cancer research institutions in the US, the Fred Hutchinson Center Research Center,where he has served for seven years. While there, he led the institution’s clinical research support and industry relations, including clinical trial and sponsored research agreements, among other roles. Mueller also managed the formation of new companies based on the Hutchinson Center’s discoveries.
“This appointment starts the build-out of Bio-Path in order to more effectively and efficiently move our technology through the development process, ultimately creating a pipeline of new liposomal antisense product candidates,” Nielsen explained.
Read other articles about Bio-Path Holdings:
[feed url=”http://bionews-tx.com/news/news-tags/bio-path-holdings/feed” number=”5″ ]
Bio-Path’s new Chief Operating Officer has also worked at the Hutchinson-University of Washington comprehensive cancer consortium, and at the University of Texas MD Anderson Cancer Center. In his role at Hutchinson-University of Washington, he managed research activities such as clinical staff training, regulatory affairs, trial monitoring, and protocol development. While at MD Anderson, he directed the Office of Technology Commercialization, where he was responsible for managing the office’s activities, including negotiating contract terms for licensing of the institution’s intellectual property.
“I have known and monitored Bio-Path for many years and I am excited to join the Company, particularly at this juncture in its growth”, said Mueller. “I look forward to expanding upon the work already done with its lead compound, Liposomal Grb-2, and to building a team that continues the goal of utilizing our proprietary liposomal delivery technology to develop therapeutic candidates in cancer and potentially other disease areas.”
With a Ph.D. in cell and molecular biology from Baylor College of Medicine, a Master of Science, Biology from Texas A&M University, and a Bachelor of Science, Microbiology from New Mexico State University, Mueller currently holds several board and advisory positions.
Bio-Path Holdings is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology. The company’s goal is to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion.